Enrollment Begins for Phase 1 Study of Eisai’s Orexin-2 Receptor Agonist E2086 in Narcolepsy

Published Date: 22 Aug 2024

The double-blind, single-dose, 5-period crossover study is expected to include approximately 40 patients with narcolepsy type 1 to test 3 dose strengths of E2086.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot